Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1288011 | 0.83 | SRC (0.55) | CNR1CYP2C19SRCEGFRMAPT | |
| SCHEMBL9037475 | 0.82 | CNR1 (0.70) | CNR1CYP2C19CNR2 | |
| SCHEMBL10738511 | 0.81 | CNR1 (0.69) | CNR1CYP2C19CNR2 | |
| SCHEMBL8530974 | 0.81 | CNR1 (0.53) | CNR1CYP2C19CNR2CYP2C9 | |
| SCHEMBL9691719 | 0.79 | CNR1 (0.66) | CNR1CYP2C19CNR2 | |
| SCHEMBL10660791 | 0.79 | CNR1 (0.66) | CNR1CYP2C19CNR2 | |
| SCHEMBL9035533 | 0.79 | CNR1 (0.66) | CNR1CYP2C19CNR2 | |
| SCHEMBL4656478 | 0.79 | CNR1 (0.42) | CNR1SRCEGFRMAPTSMN1; SMN2 | |
| SCHEMBL8532949 | 0.79 | CNR1 (0.69) | CNR1CYP2C19CNR2 | |
| SCHEMBL17414512 | 0.79 | CNR2 (0.74) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | CNR1 122/4885CYP2C19 269/4885SRC 2527/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | CNR1 122/4885CYP2C19 269/4885SRC 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.